Bayer AG, whose $62 billion takeover bid was rejected earlier by Monsanto Co., said it’s confident it can overcome the seed company’s concerns about the regulatory and financing risks related to a deal that would create the world’s largest supplier of seeds and crop chemicals.
The German company said Tuesday it looks forward to further talks with Monsanto. Hours earlier, St. Louis-based Monsanto announced its board decided unanimously to spurn the all-cash offer for being too low. The U.S. company added that it believes in the benefits a merger would bring and that it respected Bayer’s business, leaving the door open for further discussions.
“We are pleased that Monsanto’s board shares our belief in the substantial benefits an integrated strategy could provide to growers and broader society,” Bayer Chief Executive Officer Werner Baumann said in a statement.
Monsanto Rejects Bayer's Proposal, Leaves Door Open
The conciliatory tone from both sides sets the stage for an improved offer from Bayer. While Monsanto has consistently traded at less than the $122-a-share offer price since the companies started discussing a deal, the stock rallied in after-hours trading Tuesday in New York following Bayer’s latest comments, rising as high as $113.49.
Shares of Bayer rose 0.4 percent to 88.72 euros as of 9:11 a.m. in Frankfurt trading, after climbing almost 4 percent yesterday.
The company can afford to pay as much as $140 a share, and the deal would still add to “double-digit” growth in earnings in the mid-term, Jeffrey Holford, an analyst at Jefferies LLC, said in a note to clients on Tuesday.
Bayer investors have speculated the company doesn’t have much headroom to offer extra cash. The break-fee demanded by Monsanto may be much higher than normal because of the risk that industry consolidation will leave potentially fewer buyers for any assets sold off by Bayer-Monsanto to satisfy regulators, Bloomberg Intelligence analyst Jason Miner said. There’s also lingering concern over whether the deal will be passed by competition authorities as the combination of both companies could account for more than 30 percent of the global crop-inputs business.
“The regulatory hurdles are higher,” Miner said by phone. “You’re involving more countries and more political hot potatoes than maybe your typical M&A.”
Monsanto is the largest seed supplier and a pioneer of genetically modified crops, which two decades on from their introduction have come to account for the majority of corn and soybeans grown in the U.S. But despite its preeminence in seeds, the company has become vulnerable to a takeover as a number of problems piled up this year. Monsanto has cut its earnings forecast, clashed with some of the world’s largest commodity-trading companies and become locked in disputes with the governments of Argentina and India.
Farmers have seen their incomes fall in the last few years amid declining commodity prices, and that’s spurred them to increasingly demand products tailored to their needs, according to Miner, one factor that’s spurring Bayer and Monsanto to consider a merger. Their combination could also create cost-savings, estimated by Bayer at about $1.5 billion after the first three years.
A similar logic is driving China National Chemical Corp.’s deal, agreed in February, to acquire Swiss pesticide maker Syngenta AG for about $43 billion. Meanwhile DuPont Co. and Dow Chemical Co. plan to merge in and then carve out a new crop-science unit.
Bayer can pay as much as $145 and still see higher earnings per share two years after the completion of the deal, Stephane Mardel, co-CEO at brokerage and advisory firm United First Partners, said in an interview. Still, the company may be starting to listen to investors who aren’t happy with the bid, said Jonas Oxgaard, an analyst with Sanford C. Bernstein & Co. in New York.
Bayer’s response to Monsanto’s rejection “certainly says they’re not going to raise it immediately,” Oxgaard said. “They’re going to engage in dialogue first.”
Despite yesterday’s rally in Bayer shares, the stock is still down since the company’s interest in a deal was first reported May 12, with some investors concerned that the drugmaker will need to raise its bid and could end up overpaying. Moody’s Investors Service on Tuesday placed Bayer’s A3 credit rating under review for a downgrade because of the Monsanto offer. Fitch also said it may cut its rating.